Endo licenses worldwide rights to Zogenix’s Sumavel DosePro; deal terminated
Executive Summary
Complementing its Frova (frovatriptan) migraine treatment, Endo International PLC licensed exclusive worldwide rights to CNS spec pharma Zogenix Inc.’s Sumavel DosePro (sumatriptan), a drug/device that’s self-administered subcutaneously for the acute treatment of migraine with or without aura, and cluster headache. Endo will acquire Sumavel’s NDA filing, finished goods inventory (worth approximately $5mm), registered trademarks, contracts, books and records, marketing materials, and product data.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice